BridgeBio Pharma, Inc.
BBP-418
limb-girdle muscular dystrophy type 2I/R9
Resolved
102days ago
FDA decision · Mar 27, 2026
What's at stake
The FDA's approval decision on BBP-418 for limb-girdle muscular dystrophy type 2I/R9 is due Mar 27, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 16h ago
“BridgeBio anticipates approval with a U.S. launch anticipated in late 2026/early 2027”